ArticleCancer cell international2022

High PPT1 expression predicts poor clinical outcome and PPT1 inhibitor DC661 enhances sorafenib sensitivity in hepatocellular carcinoma.

Jianjun Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.